Evolus Past Earnings Performance
Past criteria checks 0/6
Evolus has been growing earnings at an average annual rate of 2.1%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 46.3% per year.
Key information
2.1%
Earnings growth rate
18.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 46.3% |
| Return on equity | n/a |
| Net Margin | -30.5% |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Evolus makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 202 | -62 | 165 | 7 |
| 30 Sep 23 | 185 | -63 | 159 | 6 |
| 30 Jun 23 | 169 | -66 | 150 | 5 |
| 31 Mar 23 | 156 | -72 | 146 | 6 |
| 31 Dec 22 | 149 | -74 | 142 | 5 |
| 30 Sep 22 | 140 | -79 | 138 | 4 |
| 30 Jun 22 | 132 | -79 | 135 | 3 |
| 31 Mar 22 | 121 | -71 | 125 | 2 |
| 31 Dec 21 | 100 | -47 | 112 | 2 |
| 30 Sep 21 | 86 | -139 | 106 | 2 |
| 30 Jun 21 | 77 | -131 | 96 | 2 |
| 31 Mar 21 | 58 | -137 | 88 | 2 |
| 31 Dec 20 | 57 | -163 | 98 | 2 |
| 30 Sep 20 | 55 | -67 | 101 | 1 |
| 30 Jun 20 | 51 | -82 | 110 | 2 |
| 31 Mar 20 | 45 | -99 | 127 | 2 |
| 31 Dec 19 | 35 | -90 | 114 | 4 |
| 30 Sep 19 | 15 | -88 | 95 | 5 |
| 30 Jun 19 | 2 | -73 | 71 | 6 |
| 31 Mar 19 | 0 | -52 | 42 | 7 |
| 31 Dec 18 | 0 | -47 | 28 | 6 |
| 30 Sep 18 | 0 | -30 | 19 | 7 |
| 30 Jun 18 | 0 | -21 | 13 | 6 |
| 31 Mar 18 | 0 | -7 | 7 | 6 |
| 31 Dec 17 | 0 | -4 | 5 | 7 |
| 30 Sep 17 | 0 | -13 | 4 | 8 |
| 30 Jun 17 | 0 | -14 | 4 | 10 |
| 31 Mar 17 | 0 | -18 | 6 | 12 |
| 31 Dec 16 | 0 | -20 | 7 | 13 |
Quality Earnings: EVL is currently unprofitable.
Growing Profit Margin: EVL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EVL is unprofitable, but has reduced losses over the past 5 years at a rate of 2.1% per year.
Accelerating Growth: Unable to compare EVL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EVL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: EVL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.